MabCampath (alemtuzumab) – Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis

June 22nd, 2020
©2020 Newfoundland & Labrador Pharmacy Board